Oxidative stress levels in myelodysplastic syndrome patients: Their relationship to serum ferritin and haemoglobin values

Journal of International Medical Research

Volumn 39, Issue 5, 2011, Pages 1941-1945

  Saigo, K ^a   Takenokuchi, M ^a   Hiramatsu, Y ^b   Tada, H ^b   Hishita, T ^c   Takata, M ^d   Misawa, M ^e   Imoto, S ^f   Imashuku, S ^g  

^a HIMEJI DOKKYO UNIVERSITY   (Japan)

^b HIMEJI RED CROSS HOSPITAL   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION HIMEJI MEDICAL CENTER   (Japan)

^d Kakogawa Municipal Hospital   (Japan)

^e Akoh Central Hospital   (Japan)

^f KOBE TOKIWA UNIVERSITY   (Japan)

^g Takasago seibu Hospital   (Japan)

Author keywords

Ferritin; FRAS4; Free Radical Analytical System; Haemoglobin; Myelodysplastic Syndrome; Oxidative Stress

Indexed keywords

ANTIOXIDANT; FERRITIN; HEMOGLOBIN; IRON; IRON CHELATING AGENT; REACTIVE OXYGEN METABOLITE;

ADULT; AGED; ANEMIA; ARTICLE; BIOACCUMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FERRITIN BLOOD LEVEL; HUMAN; MALE; MOLECULAR PATHOLOGY; MYELODYSPLASTIC SYNDROME; OXIDATIVE STRESS; PROTEIN DETERMINATION; PROTEIN FUNCTION; REFERENCE VALUE;

EID: 80155141156     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001103900539     Document Type: Article

References (23)

1. Kerbauy DB, Deeg HI: Apoptosis and antiapoptotic mechanisms in the progression of myelodysplastic syndrome. Exp Hematol 2007; 35: 1739-1746.
2. Rosenfeld C, List A: A hypothesis for the pathogenesis of myelodysplastic syndromes: implications for new therapies. Leukemia 2000; 14: 2-8.
3. Farquhar MJ, Bowen DT: Oxidative stress and the myelodysplastic syndromes. Int J Hematol 2003; 77: 342-350.
4. Takatoku M, Uchiyama T, Okamoto S, et al: Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality. Eur J Haematol 2007; 78: 487-494.
5. Malcovati L: Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes. Leuk Res 2007; 31(suppl 3): S2-S6.
6. Rassool FV, Gaymes TJ, Omidvar N, et al: Reactive oxygen species, DNA damage, and error-prone repair: a model for genomic instability with progression in myeloid leukemia? Cancer Res 2007; 67: 8762-8771.
7. Fracchiolla NS, Bamonti Catena F, Novembrino C, et al: Possible association between reactive oxygen metabolites and karyotypic abnormalities in myelodysplastic syndromes. Haematologica 2003; 88: 594-597.
8. Ghoti H, Amer J, Winder A, et al: Oxidative stress in red blood cells, platelets and polymorphonuclear leukocytes from patients with myelodysplastic syndrome. Eur J Haematol 2007; 79: 463-467.
9. Winder A, Lefkowitz R, Ghoti H, et al: Urinary hepcidin excretion in patients with myelodysplastic syndrome and myelofibrosis. Br J Haematol 2008; 142: 669-671.
10. Brunning RD, Orazi A, Germing U, et al: Myelodysplastic syndromes/neoplasms, overview. In: WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues (Steven H, ed). Lyon: IARC Press, 2008; pp 88-93.
11. Yoo JH, Maeng HY, Sun YK, et al: Oxidative status in iron-deficiency anemia. J Clin Lab Anal 2009; 23: 319-323.
12. Kanaoka Y, Inagaki E, Hamanaka S, et al: Analysis of reactive oxygen metabolites (ROMs) after cardiovascular surgery as a marker of oxidative stress. Acta Med Okayama 2010; 64: 323-330.
13. Balla J, Vercellotti GM, Jeney V, et al: Heme, heme oxygenase, and ferritin: how the vascular endothelium survives (and dies) in an iron-rich environment. Antioxid Redox Signal 2007; 9: 2119-2137.
14. Choi SO, Cho YS, Kim HL, et al: ROS mediate the hypoxic repression of the hepcidin gene by inhibiting C/EBPiiand STAT-3. Biochem Biophys Res Commun 2007; 356: 312-317.
15. Kohgo Y, Ikuta K: Body iron metabolism and pathophysiology of iron overload. Int J Hematol 2008; 88: 7-15.
16. Ghoti H, Fibach E, Westerman M, et al: Increased serum hepcidin levels during treatment with deferasirox in iron-overload patients with myelodysplastic syndrome. Br J Haematol 2011; 153: 118-120.
17. Peddie CM, Wolf CR, McLellan LI, et al: Oxidative DNA damage in CD34+ myelodysplastic cells is associated with intracellular redox changes and elevated plasma tumor necrosis factor-ppconcentration. Br J Haematol 1997; 99: 625-631.
18. Kilpatrick LE, Sun S, Ki H, et al: Regulation of TNF-induced oxygen radical production in human neutrophils: role of h-PKC. J Leukoc Biol 2010; 87: 153-164.
19. Park CH, Kimler BF, Yi SY, et al: Depletion of Lascorbic acid alternating with its supplementation in the treatment of patients with acute myeloid leukemia or myelodysplastic syndromes. Eur J Haematol 2009; 83: 108-118.
20. Erikci AA, Ozturk A, Karagoz B, et al: Results of combination therapy with amifostine, pentoxifylline, ciprofloxacin and dexamethasone in patients with myelodysplastic syndrome and acute myeloid leukemia. Hematology 2008; 13: 289-292.
21. Bendova P, Mackova E, Haskova P, et al: Comparison of clinically used and experimental iron chelators for protection against oxidative stress-induced cellular injury. Chem Res Toxicol 2010; 23: 1105-1114.
22. Oliva EN, Ronco F, Marino A, et al: Iron chelation therapy associated with improvement of hematopoiesis in transfusiondependent patients. Transfusion 2010; 50: 1568-1570.
23. Sarkar FH, Li Y: NF-2B: a potential target for cancer chemoprevention and therapy. Front Biosci 2008; 13: 2950-2959.